Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin and CHP in Frontline PTCL With <10% CD30 Expression
NCT04569032Phase 2Completed
- Sponsor
- Pfizer
- Start
- Nov 2020
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of brentuximab vedotin in peripheral T-cell lymphoma (PTCL), sponsored by Pfizer. Started Nov 2020; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT04569032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04569032.